Atom | Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on The Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic (UPS) Opioids (R01 Clinical Trial Not Allowed)

Due Dates: November 18, 2025 | November 18, 2026 | November 18, 2027

Funding Amounts: Up to $300,000 direct costs per year; maximum project period of 5 years; NIH intends to support up to 4 awards (total program funding $2M in FY26)

Summary: Supports basic research on mechanisms and mitigation of acute and persistent effects of ultra-potent synthetic (UPS) opioid exposure (e.g., fentanyl, carfentanil, nitazenes, and combinations such as fentanyl and xylazine).

Key Information: Clinical trials are not allowed; focus must be on DHS chemicals of concern; non-domestic organizations are not eligible.

Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on The Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic (UPS) Opioids (R01 Clinical Trial Not Allowed)

Sign in to see full grant listing